DBV Technologies (NASDAQ:DBVT) Shares Gap Down - Here's What Happened

Key Points

• DBV Technologies shares opened lower, falling from a previous close of $11.76 to $11.30 before trading at approximately $11.32 on volume of 90,769 shares.
• Analyst sentiment remains mostly positive: five analysts rate the stock Buy and one rates it Sell, producing a consensus “Moderate Buy” rating and an average price target of $48.50.
• Institutional investors and hedge funds own 71.74% of the company, while DBV focuses on Viaskin, including its investigational peanut-allergy treatment for children.

DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report)'s stock price gapped down prior to trading on Thursday. The stock had previously closed at $11.76, but opened at $11.30. DBV Technologies shares last traded at $11.32, with a volume of 90,769 shares changing hands.

Analyst Upgrades and Downgrades

DBVT has been the topic of several analyst reports. Citigroup reaffirmed a "market outperform" rating on shares of DBV Technologies in a research report on Wednesday. Wall Street Zen cut shares of DBV Technologies from a "hold" rating to a "sell" rating in a report on Saturday, July 4th. HC Wainwright restated a "buy" rating on shares of DBV Technologies in a report on Tuesday, June 30th. Weiss Ratings lowered DBV Technologies from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Friday, July 17th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of DBV Technologies in a research note on Thursday, September 10th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $48.50.

DBV Technologies Stock Performance

The company has a market cap of $699.79 million, a PE ratio of -3.17 and a beta of -0.95. The stock's 50-day simple moving average is $13.36 and its 200 day simple moving average is $16.64.

Institutional Investors Weigh In On DBV Technologies

Hedge funds have recently added to or reduced their stakes in the company. Vivo Capital LLC boosted its stake in shares of DBV Technologies by 8.4% in the first quarter. Vivo Capital LLC now owns 2,667,569 shares of the company's stock valued at $55,726,000 after buying an additional 205,943 shares in the last quarter. ADAR1 Capital Management LLC acquired a new position in DBV Technologies during the first quarter worth $21,159,000. Perceptive Advisors LLC acquired a new stake in DBV Technologies in the first quarter valued at $20,146,000. Atika Capital Management LLC increased its position in shares of DBV Technologies by 31.1% in the first quarter. Atika Capital Management LLC now owns 271,300 shares of the company's stock valued at $5,667,000 after buying an additional 64,419 shares in the last quarter. Finally, Elmind Capital LP acquired a new position in DBV Technologies during the first quarter worth about $5,536,000. Institutional investors and hedge funds own 71.74% of the company's stock.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. The company's lead technology, Viaskin, is designed to deliver targeted immunotherapy through the skin without requiring an injection. Its approach is intended to expose the immune system to controlled amounts of an allergen while limiting systemic exposure.

DBV Technologies' primary product candidate is Viaskin Peanut, an investigational patch intended to treat peanut allergy, particularly in children.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.